Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
MGAT2 inhibitor decreases liver fibrosis and inflammation in
A Class of Diacylglycerol Acyltransferase 1 Inhibitors Identified
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic
US9365558B2 - Dihydropyridinone MGAT2 inhibitors - Google Patents
Novel antisense inhibition of diacylglycerol O-acyltransferase 2
Targeted therapeutics and novel signaling pathways in non-alcohol
Lipid metabolic flux analysis of compA in intestinal mucosa
Pharmacotherapies of NAFLD: updated opportunities based on
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2
NASH Drug Development: Seeing the Light at the End of the Tunnel?
Therapeutic Strategies for Metabolic Diseases: Small‐Molecule
The monoacylglycerol acyltransferase pathway contributes to
de
por adulto (o preço varia de acordo com o tamanho do grupo)
